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ABSTRACT 
 
Bacterial vaginosis (BV), a common female reproductive tract (FRT) condition characterized by 
an overgrowth of anaerobic species concurrent with the disappearance of commensal 
Lactobacilli species, is associated with a 60% increased risk of HIV-1 transmission. However, 
the role of the FRT epithelia in bacterial vaginosis-associated bacteria (BVAB)-augmented HIV-
1 transmission is unclear. To evaluate the increased risk of HIV-1 acquisition, we treated FRT 
epithelia with Atopobium vaginae, a prevalent BVAB, to determine the nature of the host 
response to BVAB exposure. Treatment of endocervical cells with A. vaginae resulted in a 1500-
fold increase in the expression of the antimicrobial peptide hBD-2, an inflammatory cytokine 
response, and delocalization of the tight junction protein ZO-1 from cell borders. Conditioned 
media (CM) from the coculture of FRT epithelia and A. vaginae also generated an inflammatory 
immune response and lowered the transepithelial electrical resistance in polarized endocervical 
monolayers. Changes in HIV-1 infection were measured in TZM-bl reporter cells, which contain 
a luciferase gene under the control of an HIV-1 long terminal repeat (LTR) region that is 
activated by the binding of Tat, an HIV-1 protein that drives viral replication. NFκB is a major 
host-derived transcription factor that regulates the expression of many genes involved in 
inflammation and the innate immune response. Interestingly, NFκB has been reported to bind 
Tat-activated response elements within the LTR of HIV-1, driving viral transcription. TZM-bl 
cells were treated with CM in the absence of HIV-1, which resulted in increased luciferase 
production that could be suppressed by the NFκB inhibitor TPCA-1. These data suggest that 
epithelially derived products from the coculture of FRT cells and A. vaginae enhance HIV-1 
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CHAPTER I: INTRODUCTION 
The human immunodeficiency virus (HIV) continues to be a worldwide epidemic, currently 
infecting over 34 million people [1]. There is evidence of a gender discrepancy in the infection 
rate, especially in Sub-Saharan Africa where over 60% of new infections occur heterosexually in 
women [2]. Therefore, as the predominantly affected group, studying and preventing infection in 
women can have significant impact on the overall reduction of global HIV infection. As the 
primary route of infection occurs through mucosal surfaces, mainly through heterosexual 
transmission, further studies of the interaction between HIV and the female reproductive tract 
(FRT) epithelia can help identify new ways to reduce HIV infection in women [3]. 
 
Heterosexual HIV transmission mainly occurs through the epithelium of the lower FRT, 
targeting immune cells such as T cells, macrophages, and dendritic cells which are located below 
the epithelium [4]. The lower FRT consists of the vagina, the ectocervix, and the endocervix. 
The vagina and ectocervix consist of multiple layers of non-keratinized squamous epithelium, 
while the endocervix consists of single-layer columnar epithelium. It is currently believed that 
the endocervix is especially susceptible to HIV infection compared to the vagina and ectocervix 
due to its single layered nature and the higher concentration of CD4+ T cells, the main target cell 
for HIV replication, in the region [5].  
 
Heterosexual HIV transmission to women is typically low, ranging from 1/100 to 1/1000 sexual 
acts [6, 7]. HIV virions must 1) survive a low pH vaginal environment consisting of 
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cervicovaginal fluid, which contains a variety of antimicrobial peptides that help fight off 
invading pathogens; 2) traverse the epithelium of the FRT to target host immune cells that reside 
below the epithelium; and, 3) be efficiently replicated by host immune cells that travel to 
regional lymph nodes [4, 8]. The cervico-vaginal fluid is a mixture of fluids from the uterus, 
cervix, oviducts, and cervical vestibular glands. This fluid contains a variety of antimicrobial 
peptides, chemokines, and cytokines that together demonstrated shown anti-HIV activity [9]. The 
upper layers of the epithelium in the lower tract are also regularly sloughed off, which constantly 
removes pathogens from the tract [10]. The epithelium itself also confers innate immunity as it 
acts as a physical barrier to transmission of virions to underlying immune cells. Virions can pass 
through the epithelium by traversing through gaps in a compromised epithelial barrier, by 
transcytosis through epithelial cells, or paracellular movement between epithelial cells [4].  
 
The barrier function of epithelial cells is conferred by three types of cell-to-cell adhesions that 
work to seal gaps between epithelial cells: the tight junction, adherens junction, and 
desmosomes. The tight junction is comprised of multiple proteins: occludins, claudins, and 
junctional adhesion molecules. Those proteins are anchored to cytosolic proteins and seal the 
gaps between neighboring epithelial cells. The adherens junction is located below the tight 
junction and is the main connection that joins cells together by connecting their actin filaments. 
Similarly, desmosomes connect keratin filaments together. The structure is highly dynamic, 
quickly responding to a variety of stimuli either to seal intercellular gaps or allow small particles 
to pass through. Together, the three adhesive components organize the epithelia into a semi-
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permeable, polarized barrier that regulates particle diffusion and can hinder HIV translocation 
[11, 12].  
 
The innate immune system can provide over 99% immunity in HIV infection to healthy women 
[6, 7]. However, it can be postulated that common gynecological conditions can alter the FRT 
and its innate defense capabilities. One condition that may contribute is bacterial vaginosis (BV). 
BV is an idiopathic condition where the Lactobacilli-dominated healthy vaginal microbiota shifts 
to a microbiota consisting mainly of anaerobic bacteria [13]. Commonly identified bacterial 
vaginosis associated bacteria (BVAB) include Gardnerella vaginalis, Atopobium vaginae, 
Mobiluncus curtisii, and Prevotella bivia [13-15]. The relative scarcity of clinical data has made 
it difficult to determine the exact polymicrobial composition of the BV microbiota. In addition, 
many of the species associated with BV are also present in some healthy women [13, 16, 17]. 
The role that each species plays in the pathogenesis of the condition is unclear, a fact that is 
further exacerbated by the limtations on current FRT model systems that can replicate the 
physiological properties of the FRT epithelia in order to more accurately explore host-pathogen 
interactions.  
 
In healthy vaginal conditions, Lactobacillus species mainly colonize the epithelium, producing 
hydrogen peroxide and lactic acid, which help maintain an acidic (pH<4.5) environment [16]. 
While it is currently unknown which occurs first, BV is characterized by an overgrowth of 
anaerobes in the vagina concurrent with a depletion of Lactobacillus species [13]. This is 
indicated by a raise in pH, abnormal vaginal discharge, and the presence of bacteria adhering to 
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epithelial cells, according to the Amsel criteria [18]. The Nugent score is also used to diagnose 
BV, which is based on the microscopic examination of vaginal smears. The presence and 
quantity of clue cells, epithelial cells whose edges are covered by small coccobacilli, are used to 
determine the lack or severity of infection [19].  BV has been associated with a 60% increased 
transmission rate of HIV among other complications such as preterm delivery, inflammation, and 
increased risk of contracting other STIs and infections [13, 20, 21]. In some symptomatic cases, 
symptoms are self-relieving. However, many women seek treatment, most commonly with 
metronidazole or clindamycin [13, 22]. Current research is exploring the possibility of probiotics 
as an effective treatment for BV [23].  
 
Currently the link between BV and HIV is not clear though several explanations have been 
postulated: 1) The inflammatory response to BVAB can damage the mucosa, and cause an 
increase in chemotaxis and activation of CD4+ T cells to the site, which may facilitate HIV 
infection [15, 24]. 2) The increase in pH following the reduction in lactobacilli increases CD4+ T 
cell activation and proliferation. 3) When the pH is increased in BV, the negative surface charges 
on virions remain intact, allowing for higher rates of HIV diffusion through the mucosa for 
higher accessibility to target cells below [25].  
 
One aspect of BV that remains to be elucidated is the role of the female reproductive tract 
epithelia in BVAB-augmented HIV transmission and infection. One of the methods of HIV 
transmission is translocation through gaps in the epithelium, which is held together by cell-cell 
adhesions [4]. In BV, the endocervix is exposed to pathogenic bacteria, and our lab previously 
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showed that in End1 cells, an endocervical epithelial cell line [26], BVAB elicit a robust 
inflammatory response that includes marked increases in expression of β-defensins, 
inflammatory cytokines and chemokines, as well as other immune modulators such as lipocalin-
2, trappin-2, cyclophilin A, and HE4. In End1 cells, the most pronounced response occurred after 
exposure to A. vaginae. Together, these host defense factors exhibited HIV-enhancing effects on 
TZM-bl target cells [27]. Concurrently, other groups have shown that upregulated cytokine 
expression may regulate cell-cell junctions via changes in expression and localization of proteins 
such as occludin, claudin-1/5, ZO-1/2, E-cadherin, and beta-catenin [28]. These proteins are 
components of tight junctions and serve as markers for epithelial integrity [11].  
 
We confirmed the inflammatory response in FRT cells in response to BVAB, particularly A. 
vaginae, and showed that this exposure also reduces the expression of the tight junction protein, 
ZO-1, intracellularly. We sought to confirm the barrier disruption by creating an FRT polarized 
monolayer model using A2EN cells, an endocervical cell line, on Transwell inserts. This model 
represents an improvement upon the previous in vitro model used to explore the host-pathogen 
interactions, and we were able to observe distinct changes in barrier function after treatment with 
conditioned media from BVAB-treated FRT epithelia. We also report evidence that this 





CHAPTER II: MATERIALS AND METHODS 
Cell lines 
 
End1 (human endocervical epithelia) and Ect1 (human ectocervical epithelia) cell lines were 
obtained from the American Type Culture Collection (ATCC) and were maintained with 
keratinocyte serum-free media (KSFM) supplemented with epidermal growth factor, calcium 
chloride, and bovine pituitary extract (Life Technologies). A2EN (human endocervical epithelia) 
cell line was obtained from Dr. Alison J. Quayle (Louisiana State University Health Science 
Center, New Orleans, LA) and maintained with EpiLife media (Cascade Biologics) 
supplemented with Epilife Defined Growth Supplement and calcium chloride.  TZM-bl cell line 
was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: TZM-bl 
from Dr. John C. Kappes, Dr. Xiaoyun Wu and Tranzyme Inc. 
Bacterial cultures 
 
Lactobacillus crispatus, Lactobacillus johnsonii, Mobiluncus curtisii, Atopobium vaginae, 
Prevotella bivia, and Gardnerella vaginalis were obtained from the ATCC. The Lactobacilli 
strains were cultured in Man, Rogosa and Sharpe (MRS) agar in 37°C 5% CO2 for 48 hours. The 
remaining strains were cultured in tryptic soy broth containing 5% defibrinated rabbit blood in 
37°C with anaerobic GasPaks for 72 hours. Cultures of each are pre-prepared, aliquoted, and 
snap frozen for fresh use in experiments. 
Cell culture treatment for End1/Ect1/A2EN experiments 
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Confluent dishes of cells were treated either supplemented KSFM (mock) or bacteria diluted in 
supplemented KSFM. Supplemented KSFM and resuspended bacteria were also incubated in 
cell-free conditions as a control. Bacterial cultures taken directly from snap-frozen aliquots were 
centrifuged at 13,000 x g for 5 minutes at room temperature and resuspended in appropriate cell 
growth medium at a final multiplicity of infection (MOI) of 10 bacteria per cell. The bacteria 
were then placed on confluent cells in 100mm dishes and incubated at 37°C/5% CO2 for 24 
hours. MOI was confirmed through a serial dilution of the starting bacterial culture on the 
appropriate media to back calculate the number of bacterial colony forming units actually used to 
treat the cells.  
 
Generation and processing of conditioned media 
 
End1 cells were grown to confluence on 100mm tissue-culture treated plates and treated as 
described above with either a mock (supplemented KSFM) or A. vaginae. Conditioned media 
(CM) from all treatments was collected and clarified at 4000 x g at 4°C for 10 minutes. CM from 
each treatment was pooled to 15mL, which was then concentrated to 15X to be desalted. For 
future use in cell treatments, samples were desalted with an Amicon Ultra- 0.5mL Centifugal 
Filter with a 3kDa molecular weight cutoff (EMD Millipore). The sample was filtered and 
washed twice with molecular grade water, resulting in a final salt concentration below 1X. 
Molecular grade water was used to bring final protein concentration back to 15X, and samples 
were stored at -20°C until use. Both cell-free KSFM and A. vaginae conditions are processed by 
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the above procedure as well. For convenience, conditioned media samples are labeled as follows: 
A) Cell-free KSFM B) Cell-free A. vaginae C) End1/KSFM D) End1/A. vaginae.  
Real-time polymerase chain reaction 
 
Confluent End1 cells were treated with same treatment scheme and harvested with TRIzol 
reagent (Invitrogen). Total RNA was extracted, and contaminating genomic DNA was removed 
(Ambion’s DNA-free kit). 200ng of total RNA was used to create cDNA with iScript cDNA 
synthesis according to manufacturer instruction (Bio-Rad). Real-time PCR was performed using 
TaqMan Gene Expression Master Mix with PrimeTime Std qPCR Assay kit (Life Technologies) 
for desired gene according to the following program: (Cycle 01) 50°C for 2 minutes, (Cycle 02) 
95°C for 5 minutes, (Cycle 03) 95°C for 15 seconds followed by 60°C for 1 minute (40X). The 
housekeeping genes, GAPDH and 18S, were used as a quantitative control to which all samples 
were normalized to. PCR products were confirmed via 1.5% agarose gel electrophoresis.  
Immunofluorescence  
 
A2EN cells were grown on coverslips coated with poly-L-lysine and treated as described above 
with either a mock (supplemented EpiLife) or A. vaginae. Cells were fixed in 0.4% 
paraformaldehyde. Cells were then processed with Image-iT Fix-Perm kit (Life Technologies) 
according to company instructions. Briefly, cells were permeabilized and blocked with the 
provided buffers. Image iT FX signal enhancer (Life Technologies) was applied, and a 
monoclonal ZO-1 primary antibody (conjugated to FITC) (Invitrogen, ZO1-1A12) was diluted in 
the provided block buffer and incubated with the coverslips overnight at 4°C. Nuclear staining 
was performed with Hoechst 33528 nuclear stain (Life Technologies) followed by slide 
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mounting with ProLong Diamond Anti-Fade mounting media (Life Technologies). Slides were 
cured overnight and viewed. 
A2EN Transwell model  
  
24W Transwells inserts (Corning Incorporated) were coated with Human Placenta Derived 
Extracellular Matrix (Corning Incorporated) before use. A2EN cells were seeded onto the 
Transwell insert at 25,000 cells/well and maintained with apical and underlay supplemented 
EpiLife media containing a final calcium chloride concentration of 0.4mM at 37°C/5%CO2. At 
10 days past seeding, the transepithelial electrical resistance (TEER) was measured to confirm 
the initial polarization; and apical media was removed to allow the cells to mature at air-liquid 
interface. After 3-5 days at air-liquid interface, TEER was measured to confirm complete 
polarization, and cells were treated at this point. Cells were considered a polarized monolayer 
when reaching a TEER of approximately 250-300 Ωcm2 
NFκB Assays  
 
TZM-bl cells were seeded on a 96-well black, clear bottom plate and grown to 60-80% 
confluence. If an inhibitor, TPCA-1 (Tocris Bioscience), is tested, the inhibitor was applied 
overnight the previous day to the experiment. On the day of the experiment, CMs were diluted in 
2X DMEM/2%FBS to maintain appropriate salt concentration. Treatments were added to the 
TZM-bl cells. If necessary, HIV was diluted in 1X DMEM/1% FBS and placed on the cells at 
this point as well. The plate was then allowed to incubate for 24h in 37°C/5%CO2. Treatment 
media was removed from the cells, which were then lysed with Glo Lysis Buffer (Promega) and 
allowed to complete one freeze-thaw cycle. Upon thaw, BrightGlo Reagent (Promega) was 
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CHAPTER III: RESULTS 
BVAB exposure results in an FRT innate immune response 
 
The inflammatory response of the FRT to BVAB was previously proposed to result in increased 
HIV transmission risk as a result of chemotaxis of immune target cells creating a higher local 
concentration for potential infection [15].  We initially hypothesized that the BVAB exposure to 
FRT epithelial cells will also result in a decrease in barrier function that would allow more HIV 
virions to translocate the epithelia to the immune target cells below. To test the effect of BVAB 
exposure to FRT epithelia, we first confirmed the inflammatory response of the FRT epithelia 
using End1 cells, an endocervical cell line. Real-time TaqMan PCR was used to probe for the β-
defensin, hBD-2, as a measure of the responsiveness of the cell line to pathogenic exposure. 
Exposure to A. vaginae resulted in a significant 1200-fold increase in hBD-2 expression (Figure 
1). These results agree with previous data showing that A. vaginae elicits the most robust 




Figure 1. hBD-2 Expression in End1 Cells. Confluent End1 cells were treated with either a commensal bacterium 
(L. johnsonii) or BVAB for 24 hours in anaerobic conditions. The cells were lysed and RT-PCR was used to probe 
for expression of hBD-2 relative to a mock control condition. Bars represent the average and for two experiments.  
 
After confirming the responsiveness of our FRT cell line, we wanted to determine whether the 
BVAB exposure resulted in changes in the innate barrier function by analyzing changes in ZO-1 
expression, a tight junction protein, using Western blot. Results with this cell line, however, were 
inconclusive as the commercial antibody failed to identify a distinct band for ZO-1. 
A2EN cells polarize in a Transwell model 
 
End1 cells were not suitable for analysis of tight junctions via Western blot. We attempted to 
produce a polarized End1 monolayer on Transwell inserts and determine barrier function through 
transepithelial electrical resistance (TEER) measurements. According to company specifications, 
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a completely polarized monolayer has TEER values ranging between 200-300 Ωcm2 based on 
positive control tested at various media temperatures (Figure 2C). The End1 and Ect1 cell lines 
were unable to produce polarized monolayers and did not produce TEER values above the 
positive control for a polarization. As a result, we generated a new in vitro FRT model that was 
more physiologically relevant, containing intact barrier function, mucin production, and an air-
liquid interface characteristic of the lower FRT. This approach developed polarized monolayers 
with complete barrier function using the endocervical A2EN cell line (Figure 2B). At 10 days 
post-seeding, TEER values plateaued between 300-380 Ωcm2 and were considered mature with 




Figure 2. A2EN Cells Produce Polarized Monolayer A) Transwell insert with no cells seeded on membrane B) 
Transwell insert with confluent A2EN monolayer on membrane C) Calibration results of the EVOM2 voltohmeter 
using an ECM-coated Transwell insert and a company-provided positive control Calicell. D) A2EN cells were 
seeded onto 24 well Transwell inserts, and TEER was measured over a period of 14 days.  N=7-12 for each data 
point. (*p<0.0001 versus Calicell) 
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A2EN submerged cells respond to BVAB and CM exposure 
 
A2EN cells were cultured on coverslips and treated with commensal Lactobacilli and BVAB to 
determine 1) their immune response to BVAB, and 2) the presence of tight junctions via Bioplex 
analysis of cytokine levels and measurement of TEER changes. A2EN cells produced an 
inflammatory response to the presence of BVAB as shown by 3 fold increases in IL-6 and IL-8 
concentration, 7-15 fold increases G-CSF concentration, 2 fold increases in GM-CSF 
concentration, 4 fold increases in MIP-1b and IP-10 concentration after treatment compared to 
the mock-treated control (Figure 3).  
 
Figure 3. A2EN Submerged Monolater Produces Inflammatory Response to BVAB A2EN cells are grown 
submerged on coverslips which are then treated with either L. crispatus (LC), L. jensenii (LJ), A. vaginae (AV), M. 
curtisii (MC), or G. vaginalis (GV) at an MOI of 10 for 24 hours. Cytokine quantification is completed by Bioplex 
analysis over three repeated experiments. (*p<0.05, **p<0.01, ***p<0.001 versus mock-treated control) 
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Figure 4. Exposure to BVAB Causes Dysregulation of Cell-Cell Junctions in A2EN Cells A) A2EN cells were 
grown on ECM-coated coverslips and treated with either a mock infection control or A. vaginae for 24 hours. Cells 
were then probed for the presence of ZO-1 (green) and counterstained with Hoechst 33528 nuclear stain (blue). B) 
End1 cells were treated with either a mock infection control or A. vaginae and lysed. Changes in ZO-1 expression 
were analyzed via RT-PCR.  
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To determine whether this response also corresponded with a decrease in barrier function, we 
used immunofluorescence to view ZO-1 expression to visualize any changes in tight junctions 
between individual cells (Figure 4A). ZO-1 expression was identified at the borders between 
untreated A2EN cells, suggesting that these cells produce tight junctions and are capable of 
polarizing as ZO-1 is a major component of barrier formation [29]. Previous real-time PCR 
analysis in a parallel endocervical cell line, End1, indicate that after BVAB exposure, there is no 
significant change in ZO-1 mRNA expression (Figure 4B). These results are supported in the 
A2EN cell line. Treatment of A2EN cells with A. vaginae results in diffuse ZO-1 presence 
throughout the cell as opposed to ZO-1 concentration at the cell-cell border. ZO-1 expression did 
not decrease; instead the ZO-1 protein was delocalized after BVAB exposure, diffusing outward 
from the cell-cell border. 
 
Polarized A2EN cells respond to CM but not BVAB exposure  
 
In addition to ZO-1 staining, we used the polarized A2EN cells to determine whether TEER 
changes as a result of BVAB exposure. Our polarized A2EN cells were treated with live BVAB 
and commensal bacteria. Surprisingly, the A2EN cells treated with BVAB exhibited a lower 
inflammatory immune response when growing at the air-liquid interface on Transwell inserts 
compared to submerged on coverslips (Figure 5). Baseline cytokine values for BVAB-exposed 
cells were lower compared to baseline measurements from submerged A2EN cells. Compared to 
the mock-treated control, cytokine concentrations were only significantly higher (2.6 fold 
increase) in G. vaginalis treatments when measuring IL-8. This result supports the decreased 
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immune response presented by the polarized A2EN cells as the IL-8 concentration for G. 
vaginalis is 95-fold lower than the IL-8 measurements for G. vaginalis treatment in submerged 
A2EN cells. BVAB treatments for A. vaginae resulted in significantly lower concentrations for 
IP-10 and G-CSF. Other treatments produced no significant changes in cytokine concentration 
compared to the mock-treated control. Overall, these results suggest that the BVAB had less 
impact on the polarized A2EN cells compared to submerged A2EN cells.  
 
We then measured the corresponding TEER values after 48 hours of treatment with commensal 
and BV-associated bacteria (Figure 6). Even after 48h, there were no significant changes in 
TEER values for any treatment except G. vaginalis compared to the mock-treated control. G. 
vaginalis treatments did not significantly decrease TEER in polarized A2EN cells compared to 
the Calicell positive control.  Combined with the lowered inflammatory response, we concluded 





Figure 5. Polarized A2EN Cells Produce Decreased Inflammatory Response to BVAB A2EN cells were grown 
on Transwell inserts at the air-liquid interface. Upon maturation, cells were treated with either L. crispatus (LC), A. 
vaginae (AV), M. curtisii (MC), or G. vaginalis (GV) at an MOI of 10. Cytokine quantification was completed by 






Figure 6. Polarized A2EN Cells' TEER Values Are Not Impacted by BVAB Exposure A2EN cells were grown 
at air-liquid interface on Transwell inserts. Upon maturation, cells were treated with either L. crispatus (LC), A. 
vaginae (AV), M. curtisii (MC), or G. vaginalis (GV) at an MOI of 10 for 48 hours at which point the TEER was 
measured. Above shows the average of three repeated samples per condition relative to the negative and positive 
controls. 
 
Previous data from our laboratory revealed that conditioned media from a coculture of A.vaginae 
and End1 cells (End1/A.vaginae CM) had a proviral effect as compared to live bacteria alone. 
We then proceeded to test whether these conditioned media caused any immune response in 
polarized A2EN cells (Figure 7). After treatment with conditioned media produced from the 
End1/A.vaginae CM, the polarized A2EN cells produced an increased inflammatory immune 
response compared to treatment with live bacteria alone. End1/A.vaginae CM produced 
significantly higher concentrations of IL-6, IL-8, IP-10, and G-CSF compared to the vehicle 
control. Conditioned media from mock-treated End1 cells (End1 CM) without BVAB was used 
as a more stringent control. Treatment with End1/A.vaginae CM resulted in significantly higher 





Figure 7. Conditioned Media from Coculture of End1 Cells and A. vaginae Induce Inflammatory Response in 
Polarized A2EN Cells A2EN cells were grown at air-liquid interface on Transwell inserts and treated with either 
water or conditioned media from End1 cells alone (End1) or a coculture of End1 cells with A. vaginae 
(End1/A.vaginae) for 48 hours. Cytokine quantification was accomplished via Bioplex testing, over three repeated 
samples.  (*p<0.05 versus water, **p<0.01 versus water, ***p<0.001 versus water, ****p<0.0001 versus water, 
p<0.05 versus End1, p<0.01 versus End1) 
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We then determined whether this increased immune response affected the barrier function of the 
polarized A2EN cells by measuring their TEER values after treatment with conditioned media 
from End1 cells and End1 cells cocultured with A. vaginae compared to additional controls: 
vehicle, desalted KSFM, and conditioned media from cell-free A. vaginae incubated in KSFM 
(Figure 8). Compared to the vehicle control, all TEER measurements were significantly 
decreased for the other controls and treatment. The cell-free A. vaginae conditioned media and 
End1 CM controls were also significantly lower than the desalted KSFM controls, however the 
End1/A.vaginae CM treatment resulted in significantly decreased TEER compared to every 
control. This increased immune response followed by decreased TEER measurements in the 
polarized A2EN cells after treatment with the End1/A.vaginae CM suggests that epithelially 
derived products from the coculture of End1 cells and A. vaginae are the effectors rather than the 




Figure 8. Conditioned Media from Coculture of End1 Cells and A. vaginae Reduce TEER in Polarized A2EN 
Cells A2EN cells were grown at air-liquid interface on Transwell inserts. Upon maturation, cells were treated with 
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conditioned media for 48 hours at which point the TEER was measured. Above shows the average of three repeated 
samples per condition relative to the negative and positive controls. (*p<0.05 versus KSFM, **p<0.01 versus 
KSFM,  p<0.05 versus cell-free A.vaginae and End1 conditioned media controls) 
CM shows HIV-enhancing activity potentially through NFκB activation 
 
We reasoned that the End1/A.vaginae CM contained the effector molecules that induce barrier 
dysfunction for a potential HIV-enhancing effect, and we wanted to explore the pathway by 
which these effectors function. In TZM-bl cells, luciferase production is under the control of the 
HIV-1 long terminal repeat (LTR). Activation of the HIV-1 LTR can occur through binding of 
the HIV-1 tat protein to the Tat-responsive region (TAR) after tat is produced from the integrated 
virus. Tat then increases transcription of HIV genes and activates NFκB signaling pathways [30, 
31]. NFκB is a transcription factor whose activation and subsequent signaling pathway that has 
been associated with increased HIV transcription and replication through binding its recognition 
sequence on the HIV-1 long terminal repeat [32]. Through these processes, HIV infection and 
replication in TZM-bl cells can be determined as a function of luciferase production as measured 
by production of luminescence.  End1/A.vaginae CM containing only the 3-30kDa fraction was 
previously shown to increase HIV infection of TZM-bl cells, indicated by increased 
luminescence values after the treatment [27]. To determine the pathway by which these CMs act 
provirally, we tested the End1/A.vaginae CM alone on TZM-bl cells to determine whether 
effectors in the CM could activate the HIV-1 LTR to produce luciferase on its own. Even 
without the presence of HIV-1 tat, the End1/A. vaginae CM increased the tat-induced luciferase 
production in TZM-bl cells by 3-fold compared to the control.  As the proviral activity did not 
require HIV-1 tat, we tested to determine whether luciferase was produced from NFκB activation 
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of the HIV-1 LTR. This was tested by treating TZM-bl cells with End1/A.vaginae in the 
presence of the NFκB inhibitor, TPCA-1. Presence of the inhibitor resulted in significantly 
decreased luminescence in all samples both with and without the presence of HIV to drive 






Figure 9. TPCA-1 Treatment Results in Decreased HIV-1 Infection in TZM-bl Cells in Presence of CM TZM-
bl cells were treated with either TPCA-1, an NFκB inhibitor, or DMSO vehicle 24 hours prior to the experiment. 
Subsequently, cells were treated with conditioned media in absence or presence of HIV, as well as with and without 
TCPA-1 for 24 hours. Luminescence values (RLU/5sec for each well) were measured, and bars represent mean+/-
SEM, n=3. (*p<0.05, **p<0.01 ***p<0.001 compared to vehicle-control for each condition) 
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CHAPTER IV: DISCUSSION 
HIV transmission in the FRT is an unlikely event due in part to the layers of innate immunity 
present in the FRT [6, 7]. However, some gynecological conditions, such as BV, are associated 
with increased risk of HIV transmission in the host, possibly through mechanisms that affect the 
innate immunity [4, 20]. Previous studies have shown that exposure of the FRT cells in vitro to 
BVAB result in an inflammatory response [15], with which our data agrees. While it has been 
suggested that the increased HIV transmission risk is due in part to chemoattractants secreted in 
the inflammatory response [15], our studies explored the role of the epithelial barrier in this 
relationship.  
 
We demonstrated an inflammatory response in our endocervical cell lines, End1 and A2EN, after 
exposure to live BVAB. However, only the A2EN cell line was capable of producing tight 
junctions in order to measure if the immune response also resulted in changes in barrier function. 
This is in agreement with previous literature showing that End1 cells do not polarize [33]. 
Immunofluorescence probing for ZO-1 in A2EN cells on coverslips revealed a change in ZO-1 
localization, implying a dismantling of tight junctions, after exposure to BVAB. However, in our 
polarized A2EN cells, live bacterial treatments elicited a lower cytokine response than in the 
submerged A2EN cells and  little significant impact on barrier function as measured by TEER. 
This could be a result of the more physiologically accurate representation that this approach 
provides. Polarized A2EN cells have additional defenses produced at air-liquid interface, such as 
mucus production [34], which may have inhibited the bacteria from eliciting effects from the 
epithelial cells.  
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TEER values decreased when the polarized A2EN cells were treated with conditioned media 
from the coculture of A. vaginae with End1 cells. We determined that epithelially derived 
products in the conditioned media were the effectors that disrupted the epithelial barrier as a 
result of an increased cytokine response and decreased barrier function compared to live 
bacterial treatment of polarized A2EN cells. This supports previous data from our laboratory 
suggesting that low-weight molecules in BVAB conditioned media acted to enhance viral 
infection [27].  
 
In addition to analysis of barrier dysfunction, we also assayed our CMs for other mechanisms 
that promote HIV-enhancing activity. Previous data concludes that the 3-30kDa fraction from 
End1/A. vaginae CMs have HIV-enhancing activity from data showing increased luciferase 
production when TZM-bl cells were treated with End1/A.vaginae CM in the presence of HIV, 
relative to the control [27]. Our data using whole, unfractionated CM support these results as the 
End1/A. vaginae CM condition shows the highest luminescence values when used to treat TZM-
bl cells with HIV present. Unexpectedly, the conditioned media generated from only End1 cells 
mock-treated with KSFM (End1 CM) also resulted in an increase in HIV infection of TZM-bl 
cells. As the lower FRT environment is typically antimicrobial and antiviral, we expected this 
condition to inhibit HIV infection in the TZM-bl cells. However, all conditioned media were 
produced from supplemented KSFM and then concentrated to 15X. The concentrated 
supplemented proteins, BPE and EGF, may have played a role that affected interaction between 
the TZM-bl cells and the HIV virions, thus producing the increased luciferase expression.  
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We also demonstrate that, even without the presence of HIV, End1/A. vaginae CMs are able to 
induce production of tat-driven luciferase in TZM-bl cells, suggesting that their proviral activity 
may involve other activators of the HIV-LTR. After treatment with TPCA-1, an NFκB inhibitor 
[35], we observed that in every condition, there is significantly lower luminescence and therefore 
luciferase expression in the TZM-bl cells. Decreased luciferase production in the presence of 
TPCA-1 suggests that NFκB can act independently of HIV-1 tat to activate the HIV-1 LTR. The 
CMs may activate an NFκB pathway to produce its HIV-enhancing effects by activating HIV-1 
LTR. As NFκB is known to drive HIV transcription and replication [32], the HIV-enhancing 
activity of effectors in End1/A.vaginae CMs may be due to its ability to both increase HIV 
replication efficacy and allow more virions to reach target cells through barrier dysfunction.  
 
We have yet to form a conclusion on whether the decreased TEER in the polarized A2EN cells 
translates into increased HIV translocation through the epithelial layer. Also, in previous studies, 
the 3-30kDa CM fractions were created to find the specific effector molecules that induce this 
HIV-enchancing activity in the presence of HIV [27]. It has not been tested yet whether those 
HIV-enhancing effectors in TZM-bl cells are also the same effectors that reduce TEER in the 
polarized A2EN cells. We have not to explored whether there are additional proteins that have 
HIV-enhancing activity present in our whole, unfractioned CM as compared to the previously 
assayed 3-30kDa fraction. In addition, it has not yet been determined whether End1/A. vaginae 
CM increases viral replication in actual HIV targets cells, such as monocytes, T cells, or 
dendritic cells. While this is more physiologically relevant, the actual HIV target cells typically 
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require high serum conditions to survive, proliferate, and propagate HIV; however 10-20% 
serum masks the activity of fractionated CM. This technical hurdle is the subject of current 
investigation in our laboratory. 
 
The presented studies, as well as the future proposed studies, will contribute to both the HIV and 
women’s health fields, as the role of the FRT epithelial barrier has been understudied in the 
context of BV and HIV acquisition. Part of the reason for a paucity of data in the literature may 
be due to heretofore physiologically limited in vitro models for studying the interaction between 
pathogens and the FRT epithelia. Our new model provides physiologically accurate barrier 
properties and immune responses that may help provide a novel way to study these interactions. 
Understanding how BVAB interacts with the FRT could lead to new ways to defend against BV 
and sexually transmitted infections. A more comprehensive risk analysis of BV for HIV infection 
also allows clinicians to better gauge the importance of treatment and HIV prevention measures 
for BV-positive women. This study will also provide new insight into the mechanism by which 
HIV is transmitted through the mucosa, which could one day be used to develop new methods to 
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